1. Home
  2. AOD vs CTMX Comparison

AOD vs CTMX Comparison

Compare AOD & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Total Dynamic Dividend Fund of Beneficial Interest

AOD

abrdn Total Dynamic Dividend Fund of Beneficial Interest

HOLD

Current Price

$10.51

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.77

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AOD
CTMX
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
977.1M
IPO Year
2006
2015

Fundamental Metrics

Financial Performance
Metric
AOD
CTMX
Price
$10.51
$3.77
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$12.10
AVG Volume (30 Days)
409.3K
3.1M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$8.38
$1.72
52 Week High
$10.77
$8.21

Technical Indicators

Market Signals
Indicator
AOD
CTMX
Relative Strength Index (RSI) 64.16 34.05
Support Level $9.82 $3.76
Resistance Level $10.77 $3.91
Average True Range (ATR) 0.12 0.22
MACD 0.02 -0.03
Stochastic Oscillator 88.06 9.87

Price Performance

Historical Comparison
AOD
CTMX

About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest

Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: